A 21-carbon steroid that is converted from PREGNENOLONE by STEROID 17-ALPHA-HYDROXYLASE. It is an intermediate in the delta-5 pathway of biosynthesis of GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS.
Metabolites or derivatives of PROGESTERONE with hydroxyl group substitution at various sites.
An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.
Saturated derivatives of the steroid pregnane. The 5-beta series includes PROGESTERONE and related hormones; the 5-alpha series includes forms generally excreted in the urine.
A metabolite of PROGESTERONE with a hydroxyl group at the 17-alpha position. It serves as an intermediate in the biosynthesis of HYDROCORTISONE and GONADAL STEROID HORMONES.
A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
17,21-Dihydroxypregn-4-ene-3,20-dione. A 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities.
A 21-carbon steroid, derived from CHOLESTEROL and found in steroid hormone-producing tissues. Pregnenolone is the precursor to GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS.
Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.
Plasma glycoprotein member of the serpin superfamily which inhibits TRYPSIN; NEUTROPHIL ELASTASE; and other PROTEOLYTIC ENZYMES.

Apparent activities of 21-hydroxylase, 17alpha-hydroxylase and 17,20-lyase are impaired in adrenal incidentalomas. (1/52)

OBJECTIVE: An increased response of 17-hydroxyprogesterone to ACTH stimulation has been observed in adrenal incidentaloma and linked to an impairment of either 21-hydroxylase or of 11beta-hydroxylase activity. To analyse this question further, we investigated the steroidogenic pathways in a series of 17 adrenal incidentalomas. DESIGN AND PATIENTS: 17 patients (7 women, 10 men; mean age, 62 +/- 12 years) with non-histologically analyzed adrenal incidentalomas were prospectively evaluated. METHODS: The following variables were investigated: 24-h urinary methanephrines and free cortisol excretion; plasma levels of ACTH and dehydroepiandrosterone; overnight dexamethasone suppression test; 1-24 ACTH stimulation test with measurement of: cortisol, 11-deoxycortisol, 17-hydroxyprogesterone, aldosterone, 11-deoxycorticosterone, progesterone, 17-hydroxypregnenolone, Delta4-androstenedione, dehydroepiandrosterone and 21-deoxycortisol. RESULTS: Discordant features of subclinical hypercorticism were noted in one case. No patient had dehydroepiandrosterone sulfate levels in the normal range for his or her age. Peak 17-hydroxyprogesterone and peak 21-deoxycortisol disclosed impairment of 21-hydroxylase in 11 and 10 cases respectively. An increased 11-deoxycortisol/cortisol ratio identified reduced activity of 11beta-hydroxylase in 11 patients. Eight patients displayed features of mild 17,20-lyase impairment, which was related to 21-hydroxylase dysfunction. Whereas only 2 patients showed no enzyme modification, 9 displayed alterations of at least two pathways. CONCLUSION: In our hands, a combination of enzyme dysfunction was frequently observed. Shared biochemical mechanisms could explain combined 17,20-lyase and 21-hydroxylase alterations, whereas coexistence of 21-hydroxylase (particularly when based on peak 21-deoxycortisol) and 11beta-hydroxylase is more puzzling.  (+info)

Conversion of pregnenolone to DHEA by human 17alpha-hydroxylase/17, 20-lyase (P450c17). Evidence that DHEA is produced from the released intermediate, 17alpha-hydroxypregnenolone. (2/52)

Most previous studies using reconstituted systems and fast kinetics suggest that the conversion of pregnenolone to dehydroepiandrosterone (DHEA; the precursor of androgen and estrogen biosynthesis) by P450c17 does not require the release of the intermediate 17alpha-OHPreg (a precursor of cortisol biosynthesis). With such a mechanism, it is difficult to conceive how high amounts of DHEA may be produced in some cells or tissues, such as the testis and cells from the adrenal reticularis, while in other tissues such as the fasciculata zone, high levels of 17alpha-OHPreg are synthesized. In this report, we address this matter using intact transfected cells, which better reflect the actual cellular conditions. Furthermore, by using transfected cells, we can conveniently analyze human enzymes, as we are not restricted by the availability of human tissues as in the case of methods using purified or partially purified enzymes. Using intact HEK-293 cells transfected with human P450c17 in culture, we showed, in a time course study of the transformation of pregnenolone, that there is an accumulation of 17alpha-OHPreg, and that, subsequently, the accumulated 17alpha-OHPreg decreases with a concomitant increase in DHEA production. The DHEA/17alpha-OHPreg ratio changes from 0.1 :1 after 1 h incubation to 50 : 1 after 20 h. This result strongly suggests that the transformation of Preg to DHEA proceeds through two steps in which DHEA is produced from the released intermediate 17alpha-OHPreg. We also show that high levels of substrate vs. enzyme concentration will lead to high hydroxylase activity whereas the reverse will increase the lyase activity. The result is in good agreement with recent observations suggesting that surrounding enzymes and steroids could modulate the lyase activity. Cotransfection of vectors expressing cytochrome b5 and NADPH cytochrome P450 reductase indicates that both are required for an optimum production of DHEA.  (+info)

Serum concentrations of delta 5-3 beta-hydroxysteroids in type 2 diabetes mellitus. (3/52)

We examined the serum concentrations of delta(5)-3beta-hydroxysteroids, pregnenolone (Preg), 17-hydroxypregnenolone (17-OH-Preg), dehydroepiandrosterone (DHEA), androstenediol (ADIOL) and their sulfates in 30 well controlled (Group I: HbA1c<7.0%) and 15 poorly controlled (Group II: HbA1c>7.1%) type 2 diabetic patients, and 30 normal controls. These patients were treated with diet therapy or anti-diabetic agent. The distribution of gender and age of the subjects were matched between the groups. The serum levels of sulfo-conjugated and unconjugated steroids described above were measured by GC-MS and enzyme immunoassay (EIA), respectively. The serum levels of the entire sulfo-conjugated steroid measured in this study were significantly lower in Groups I and II than in controls. On the other hand, Preg levels in both Groups I and II were significantly higher than those in controls, whereas the serum levels of the downstream unconjugated steroids were not different from controls. To investigate the effect of sulfonylurea (SU) on the serum levels of steroids, the serum concentrations of steroids between the patients who were treated with diet therapy and SU agent were compared in Group I. No significant differences were observed between both groups. These results suggest that (1) since increased Preg levels did not cause any changes in the downstream delta(5)-3beta-hydroxysteroid levels, the metabolic pathway of delta(4)-3-ketosteroids may be accelerated in type 2 diabetes; (2) serum steroid levels were not affected by SU treatment; (3) sulfo-conjugated steroid catabolism was altered in type 2 diabetes; (4) the decreased sulfo-conjugated steroids especially ADIOLS may contribute to the alteration of sex steroid levels and onset or exacerbate infectious diseases in diabetes.  (+info)

Molecular dynamics of substrate complexes with hamster cytochrome P450c17 (CYP17): mechanistic approach to understanding substrate binding and activities. (4/52)

The cytochrome P450c17 isoforms from various animal species have different substrate selectivity, especially for 17,20-lyase activity. In particular, the human P450c17 selectively produces dehydroepiandrosterone with little androstenedione (AD). Hamster P450c17, on the other hand, produces both of these steroids at comparable rates. We thus investigated if computational analysis could explain the difference in activity profiles. Therefore, we inserted the four P450c17 substrates-pregnenolone, progesterone, and their 17alpha-hydroxylated forms-inside our hamster P450c17 model, which we derived from our human P450c17 model based on the crystal structure of P450BMP. We performed molecular dynamics (MD) simulations on the complexes and analyzed the resultant trajectories to identify amino acids that interact with substrates. Starting with substrates in two different orientations, we obtained two sets of binding trajectories in each case. The first set of trajectories reveal structural rearrangements that occur during binding, whereas the second set of trajectories reflects substrate orientations during catalysis. Our modeling suggests that three distinct steps are required for substrate selectivity and binding to the hamster P450c17: (1) recognition of the substrate at the putative substrate entrance, characterized by a pocket at the surface of the hamster P450c17 containing charged residues R96 and D116; (2) entry of the substrate into the active site, in an intermediate position directed by possible hydrogen bonding of the substrates with the heme D-ring propionate group, R96, R440, and T306; followed by (3) 90 degrees counterclockwise rotation of the substrates, positioning them in optimal position for reactivity, a process that may be directed by hydrogen bonding to the 110-112 region of the hamster P450c17. With some substrates, we obtained trajectories which suggest that major distortions in the I-helix and opening of the H-I loop occur during substrate binding. In conclusion, these modeling exercises provide insight to possible structural reorganizations that occur during substrate binding and suggest that amino acids that participate in three distinct steps of this process may all contribute to substrate binding and activity.  (+info)

Steroid hormone formation in bovine ovarian follicles. (5/52)

In an attempt to assess histophysiological implication of the follicular compartment of the bovine ovary in steroid hormone formation and the effect of human chorionic gonadotropin (hCG) in vitro on follicular steroidogenesis, minces of follicular tissues from non-gravid bovine ovaries were incubated with radioactive testosterone or acetate in the presence and absence of hCG. Significant amounts of estrone and estradiol-17beta were formed on incubation with testosterone-4-14C; hCG decreased the conversion approximately by 30%. The major radioactive products formed from acetate-l-14C were androstenedione and testosterone with lesser amounts of dehydroepiandrosterone and 17-hydroxyprogesterone. In addition, small amounts of progesterone, 17-hydroxypregnenolone, estrone and estradiol-17beta were formed. Histology of the dissected follicle specimens was characterized by dominant theca cells undergoing luteinization with small amounts of granulosa cells, which showed neither proliferation nor luteinization. The pattern of distribution of radioactivity among the steroids formed from acetate-14C was considered to represent steroidogenic profile of bovine atretic follicles. The addition of hCG in vitro increased the overall incorporation of radioactive acetate into the steroids approximately by 50%, although the range of increase was not uniform in the individual steroids under the exprimental conditions.  (+info)

Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). (6/52)

Although the human sebaceous gland can synthesize cholesterol from acetate and can further metabolize steroids such as dehydroepiandrosterone into potent androgens, the de novo production of steroids from cholesterol has not been demonstrated in human skin. The goal of this study was to delineate the steroidogenic pathway upstream from dehydroepiandrosterone by documenting the presence of members of the P450 side chain cleavage system (P450scc). This system catalyzes the initial step in steroid hormone synthesis following translocation of cholesterol to the inner mitochondrial membrane. In concert with its cofactors, adrenodoxin and adrenodoxin reductase, and the transcription factor steroidogenic factor 1, P450scc converts cholesterol to pregnenolone. An SV40 immortalized human sebaceous gland cell line (SEB-1) was established in order to facilitate investigation of the P450scc system. The sebaceous phenotype of SEB-1 sebocytes was confirmed using immunohistochemistry, Oil Red O staining, and gene array expression analysis. Presence of P450scc, adrenodoxin reductase, cytochrome P450 17-hydroxylase (P450c17), and steroidogenic factor 1 was documented in human facial skin, human sebocytes, and SEB-1 sebocytes. Using immunohistochemistry, antibodies to the above proteins localized to epidermis, hair follicles, sebaceous ducts, and sebaceous glands in sections of facial skin. Results of immunohistochemistry were confirmed with Western blotting. Biochemical activity of cytochrome P450scc and P450c17 was demonstrated in SEB-1 sebocytes using radioimmunoassay. The relative abundance of mRNA for P450scc, P450c17, and steroidogenic factor 1 in SEB-1 sebocytes and sebaceous glands was compared to mRNA levels in ovarian theca and granulosa cells using real-time quantitative polymerase chain reaction. Gene array expression analysis and quantitative polymerase chain reaction indicated that mRNA for P450scc is more abundant than mRNA for both P450c17 and steroidogenic factor 1 in sebaceous glands and SEB-1 cells. These data demonstrate that the skin is in fact a steroidogenic tissue. The clinical significance of this finding in mediating androgenic skin disorders such as acne, hirsutism, or androgenetic alopecia remains to be established.  (+info)

Steroid hormone formation in human ovarian follicles in vitro. (7/52)

Ovarian follicles of 5 to 15 mm in diameter were isolated from 45 ovaries of 34 patients in the follicular and luteal phases of the cycle. Three experiments were done. In the first, follicles were minced and incubated in Krebs-Ringer bicarbonate buffer containing 1 to 2muCi of testosterone-4-14C in the presence or absence of 100 IU human chorionic gonadotropan (hCG). In the second, minced follicles were incubated with 100 muCi of sodium acetate-I-14C under identical conditions. In the third, ten follicles from a single patient in the late proliferative stage of endometrial dating were cut in halves and incubated with 100 muCi of acetate-I-14C under identical conditions. The minced follicle preparation was capable of aromatizing testosterone-4-14C into radioactive estrone and estradiol in significant amounts. Incorporation of radioactive acetate into pregenolone, progesterone, 17-hydroxypregnenolone, 17-hydroxyprogesterone, dehydroepiandrosterone, androstenedione, testosterone, estradiol and estrone was assessed by reverse dilution analysis with recrystallization to constant specific activity. The major radioactive products formed were androstenedione and 17-hydroxyprogesterone in the latter two experiments. Dehydroepiandrosterone was one of the major steroids in the second experiment. The minor products were testosterone, progesterone and pregnenolone. Smaller, but definite incorporations of radioactive acetate into estradiol and estrone occurred in the second experiment. On histological examination, the follicles were characterized by atretic changes. This distribution pattern of radioactive acetate among the steroids was considered to represent the steroidogenic profile of unstimulated or atretic follicles.  (+info)

Neurosteroid metabolism. 7 alpha-Hydroxylation of dehydroepiandrosterone and pregnenolone by rat brain microsomes. (8/52)

Two 'neurosteroids', dehydroepiandrosterone (DHEA) and pregnenolone (PREG), are converted by rat brain microsomes into polar metabolites, identified as the respective 7 alpha-hydroxylated (7 alpha-OH) derivatives by the 'twin ion' technique of g.l.c.-m.s. with deuterated substrates. The enzymic reaction requires NADPH and is stimulated 2-4-fold by EDTA. Under optimal conditions (pH 7.4, 0.5 mM-NADPH, 1 mM-EDTA), the Km values for DHEA and PREG are 13.8 and 4.4 microM respectively, and the Vmax. values are 322 and 38.8 pmol/min per mg of microsomal protein respectively. Trace amounts of putative 7 beta-OH derivatives of DHEA and PREG are detected. Oestradiol, at a pharmacological concentration of 5 microM, inhibits DHEA and PREG 7 alpha-hydroxylation. Formation of 7 alpha-hydroxylated metabolites is low in prepubertal rats and increases 5-fold in adults. Derivatives of PREG and DHEA, such as PREG sulphate, DHEA sulphate, progesterone and 3 alpha-hydroxy-5 alpha-pregnan-20-one, are known to be neuroactive. Therefore the quantitatively important metabolism to 7 alpha-OH compounds may contribute to the control of neurosteroid activity in brain.  (+info)

17-alpha-Hydroxypregnenolone is a steroid hormone that is produced in the adrenal glands and, to a lesser extent, in the gonads (ovaries and testes). It is an intermediate in the biosynthesis of steroid hormones, including cortisol, aldosterone, and sex hormones such as testosterone and estrogen.

17-alpha-Hydroxypregnenolone is formed from pregnenolone through the action of the enzyme 17α-hydroxylase. It can then be converted to 17-hydroxyprogesterone, which is a precursor to both cortisol and androgens such as testosterone.

While 17-alpha-Hydroxypregnenolone itself does not have significant physiological activity, its role in the biosynthesis of other steroid hormones makes it an important intermediate in the endocrine system. Dysregulation of its production or metabolism can contribute to various medical conditions, such as congenital adrenal hyperplasia and certain forms of cancer.

Hydroxyprogesterone is a synthetic form of the natural hormone progesterone, which is produced by the body during pregnancy to support the growth and development of the fetus. Hydroxyprogesterone is used in medical treatments to help prevent preterm birth in certain high-risk pregnancies.

There are several different forms of hydroxyprogesterone that have been developed for use as medications, including:

1. Hydroxyprogesterone caproate (HPC): This is a synthetic form of progesterone that is given as an injection once a week to help prevent preterm birth in women who have previously given birth prematurely. It works by helping to thicken the lining of the uterus and prevent contractions.
2. 17-Hydroxyprogesterone: This is a natural hormone that is produced by the body during pregnancy, but it can also be synthesized in a laboratory for use as a medication. It has been studied for its potential to help prevent preterm birth, although it is not currently approved for this use by the U.S. Food and Drug Administration (FDA).
3. 21-Hydroxyprogesterone: This is another natural hormone that is produced by the body during pregnancy, but it can also be synthesized in a laboratory for use as a medication. It has been studied for its potential to help prevent preterm birth and for its ability to reduce the risk of certain complications in women with a history of premature birth.

It's important to note that hydroxyprogesterone should only be used under the supervision of a healthcare provider, as it can have side effects and may not be appropriate for all women. If you are pregnant or planning to become pregnant and have concerns about preterm birth, it's important to discuss your options with your healthcare provider.

Fluoxymesterone is a synthetic androgenic anabolic steroid hormone. It is derived from testosterone and has been structurally modified to increase its androgenic effects while reducing its estrogenic and progestogenic activity. Fluoxymesterone is used in medical treatment for conditions such as hypogonadism, delayed puberty, and breast cancer in women. It works by replacing the missing testosterone in men or mimicking the effects of testosterone in the body.

Fluoxymesterone is known to have a high anabolic and androgenic activity, and it is commonly abused for non-medical purposes such as improving physical performance, muscle mass, and strength. However, its use for these purposes is not approved by regulatory agencies and can lead to serious health consequences.

Fluoxymesterone is available in oral form and is typically taken two to three times a day due to its short half-life. Its side effects may include acne, hair loss, liver toxicity, mood changes, aggression, and changes in sexual function. It is important to use this medication under the supervision of a healthcare provider and follow their instructions carefully to minimize the risk of adverse effects.

Pregnanes are a class of steroid hormones and steroids that contain a pregnane nucleus, which is a steroid core with a carbon skeleton consisting of 21 carbons. This structure includes four fused rings, labeled A through D, and is derived from cholesterol.

Pregnanes are important precursors for the synthesis of various steroid hormones in the body, including progesterone, which plays a crucial role in maintaining pregnancy and regulating the menstrual cycle. Other examples of pregnanes include cortisol, a stress hormone produced by the adrenal gland, and aldosterone, a hormone that helps regulate electrolyte balance and blood pressure.

It's worth noting that pregnanes can also refer to synthetic compounds that contain this steroid nucleus and are used in various medical and research contexts.

17-α-Hydroxyprogesterone is a naturally occurring hormone produced by the adrenal glands and, in smaller amounts, by the ovaries and testes. It is an intermediate in the biosynthesis of steroid hormones, including cortisol, aldosterone, and sex hormones such as testosterone and estrogen.

In a medical context, 17-α-Hydroxyprogesterone may also refer to a synthetic form of this hormone that is used in the treatment of certain medical conditions. For example, a medication called 17-alpha-hydroxyprogesterone caproate (17-OHP) is used to reduce the risk of preterm birth in women who have previously given birth prematurely. It works by suppressing uterine contractions and promoting fetal lung maturity.

It's important to note that 17-alpha-Hydroxyprogesterone should only be used under the supervision of a healthcare provider, as it can have side effects and may interact with other medications.

Dehydroepiandrosterone (DHEA) is a steroid hormone produced by the adrenal glands. It serves as a precursor to other hormones, including androgens such as testosterone and estrogens such as estradiol. DHEA levels typically peak during early adulthood and then gradually decline with age.

DHEA has been studied for its potential effects on various health conditions, including aging, cognitive function, sexual dysfunction, and certain chronic diseases. However, the evidence supporting its use for these purposes is generally limited and inconclusive. As with any supplement or medication, it's important to consult with a healthcare provider before taking DHEA to ensure safety and effectiveness.

I am not aware of a medical definition for "Cortodoxone." It is possible that this term is not recognized in the field of medicine as it does not appear to be a commonly used medication, treatment, or diagnostic tool. If you have any more information about where you encountered this term or its potential meaning, I would be happy to try and provide further clarification.

Pregnenolone is defined as a steroid hormone produced in the body from cholesterol. It's often referred to as the "mother hormone" since many other hormones, including cortisol, aldosterone, progesterone, testosterone, and estrogen, are synthesized from it.

Pregnenolone is primarily produced in the adrenal glands but can also be produced in smaller amounts in the brain, skin, and sex organs (ovaries and testes). It plays a crucial role in various physiological processes such as maintaining membrane fluidity, acting as an antioxidant, and contributing to cognitive function.

However, it's important to note that while pregnenolone is a hormone, over-the-counter supplements containing this compound are not approved by the FDA for any medical use or condition. As always, consult with a healthcare provider before starting any new supplement regimen.

Radioimmunoassay (RIA) is a highly sensitive analytical technique used in clinical and research laboratories to measure concentrations of various substances, such as hormones, vitamins, drugs, or tumor markers, in biological samples like blood, urine, or tissues. The method relies on the specific interaction between an antibody and its corresponding antigen, combined with the use of radioisotopes to quantify the amount of bound antigen.

In a typical RIA procedure, a known quantity of a radiolabeled antigen (also called tracer) is added to a sample containing an unknown concentration of the same unlabeled antigen. The mixture is then incubated with a specific antibody that binds to the antigen. During the incubation period, the antibody forms complexes with both the radiolabeled and unlabeled antigens.

After the incubation, the unbound (free) radiolabeled antigen is separated from the antibody-antigen complexes, usually through a precipitation or separation step involving centrifugation, filtration, or chromatography. The amount of radioactivity in the pellet (containing the antibody-antigen complexes) is then measured using a gamma counter or other suitable radiation detection device.

The concentration of the unlabeled antigen in the sample can be determined by comparing the ratio of bound to free radiolabeled antigen in the sample to a standard curve generated from known concentrations of unlabeled antigen and their corresponding bound/free ratios. The higher the concentration of unlabeled antigen in the sample, the lower the amount of radiolabeled antigen that will bind to the antibody, resulting in a lower bound/free ratio.

Radioimmunoassays offer high sensitivity, specificity, and accuracy, making them valuable tools for detecting and quantifying low levels of various substances in biological samples. However, due to concerns about radiation safety and waste disposal, alternative non-isotopic immunoassay techniques like enzyme-linked immunosorbent assays (ELISAs) have become more popular in recent years.

Alpha 1-antitrypsin (AAT, or α1-antiproteinase, A1AP) is a protein that is primarily produced by the liver and released into the bloodstream. It belongs to a group of proteins called serine protease inhibitors, which help regulate inflammation and protect tissues from damage caused by enzymes involved in the immune response.

Alpha 1-antitrypsin is particularly important for protecting the lungs from damage caused by neutrophil elastase, an enzyme released by white blood cells called neutrophils during inflammation. In the lungs, AAT binds to and inhibits neutrophil elastase, preventing it from degrading the extracellular matrix and damaging lung tissue.

Deficiency in alpha 1-antitrypsin can lead to chronic obstructive pulmonary disease (COPD) and liver disease. The most common cause of AAT deficiency is a genetic mutation that results in abnormal folding and accumulation of the protein within liver cells, leading to reduced levels of functional AAT in the bloodstream. This condition is called alpha 1-antitrypsin deficiency (AATD) and can be inherited in an autosomal codominant manner. Individuals with severe AATD may require augmentation therapy with intravenous infusions of purified human AAT to help prevent lung damage.

Finally, a deficiency in the related 3-alpha-hydrozysteroid dehydrogenase may also play a role in hirsutism. 3-alpha HSD is ... Deficient 3-alpha HSD activity may lead to increased tissue levels of DHT and subsequent hirsutism. [11] ... 17OH Preg = 17-alpha-hydroxypregnenolone; DHEA = Dehydroepiandrosterone; 17OH Prog = 17-alpha-hydroxyprogesterone; Andros = ... 17OH Preg = 17-alpha-hydroxypregnenolone; DHEA = Dehydroepiandrosterone; 17OH Prog = 17-alpha-hydroxyprogesterone; Andros = ...
Differential inhibition of 17alpha-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in ... genetic and functional characteristics of three novel CYP17A1 mutations causing combined 17alpha-hydroxylase/17,20-lyase ... 17 alpha-hydroxylase/17,20-lyase deficiency. Dozens of mutations in the CYP17A1 gene have been found to cause 17α-hydroxylase/ ... As a result, 17,20-lyase activity is severely reduced but 17α-hydroxylase activity is normal. As in 17α-hydroxylase/17,20-lyase ...
Hydroxylation of pregnenolone to form 17alpha-hydroxypregnenolone, pregnenolone + NADPH + H+ => 17alpha-hydroxypregnenolone + ... Pregnenolone (PREG) and NADPH + H+ react to form 17alpha-hydroxypregnenolone (17aHPREG), NADP+, and H2O. Steroid 17 alpha ... Molecular modeling of human P450c17 (17alpha-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of ... hydroxylase/17,20 lyase (CYP17A1), associated with the endoplasmic reticulum membrane, catalyzes this reaction. ...
... alpha subunit MeSH D06.472.351.576.463 - luteinizing hormone MeSH D06.472.351.576.463.249 - glycoprotein hormones, alpha ... 20-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.099 - 5-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.478 - ... alpha-msh MeSH D06.472.699.631.525.690.583.075 - beta-msh MeSH D06.472.699.631.525.690.583.115 - gamma-msh MeSH D06.472.699.631 ... alpha-msh MeSH D06.472.734.525.690.583.075 - beta-msh MeSH D06.472.734.525.690.583.115 - gamma-msh MeSH D06.472.734.525.883 - ...
Wade, J. H., Jones, J. D., Lenov, I. L., Riordan, C. M., Sligar, S. G. & Bailey, R. C., Sep 7 2017, In: Lab on a chip. 17, 17, ... Liu, Y., Denisov, I. G., Sligar, S. G. & Kincaid, J. R., Mar 17 2021, In: Journal of the American Chemical Society. 143, 10, p ... 17 othersFlory, C. M., Schumacher, R. J., OSullivan, M. G., Cao, Q., Chu, H., Lipscomb, J. D., Atkins, W. M., Gupta, K., ... Human Cytochrome CYP17A1: The Structural Basis for Compromised Lyase Activity with 17-Hydroxyprogesterone. Mak, P. J., Duggal, ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
17OH Preg = 17-alpha-hydroxypregnenolone; DHEA = Dehydroepiandrosterone; 17OH Prog = 17-alpha-hydroxyprogesterone; Andros = ... 3BHSD catalyzes the conversion of pregnenolone to progesterone (mineralocorticoid pathway), 17-alpha-hydroxypregnenolone to 17- ... alpha-hydroxyprogesterone (glucocorticoid pathway), and dehydroepiandrosterone to androstenedione (sex steroid pathway). ... Exogenous glucocorticoid therapy suppresses adrenocorticotropic hormone (ACTH) secretion and decreases pregnenolone, 17- ...
... alpha-Defensins D12.644.276.87.44 D12.776.467.87.125 D23.529.87.48 alpha-Endorphin D12.776.641.650.405.935.119 D12.776.631.650. ... alpha-Synuclein D12.776.641.860.500 D12.776.631.860.500 D12.776.637.500 alpha-Tocopherol D3.438.150.909.750.249 D3.633.100.150. ... HLA-DP alpha-Chains D12.776.543.550.423.400.420.500 D12.776.543.550.440.400.420.500 HLA-DP Antigens D12.776.543.550.423.400.420 ... HLA-DR alpha-Chains D12.776.543.550.423.400.440.100 D12.776.543.550.440.400.440.100 HLA-DR Antigens D12.776.543.550.423.400.440 ...
Pregnenolone 16 alpha-Carbonitrile Term UI T033261. Date07/13/1981. LexicalTag NON. ThesaurusID UNK (19XX). ... Pregnenolone 16 alpha-Carbonitrile Pregnenolone Carbonitrile, (3 beta)-Isomer Pregnenolone Carbonitrile, (3 beta,16 beta)- ...
Females with 17-hydroxylase deficiency appear phenotypically female at birth but do not develop breasts or menstruate in ... CYP21A is the gene that codes for 21-hydroxylase, CYP11B1 codes for 11-beta-hydroxylase, and CYP17 codes for 17-alpha- ... Basal 17-hydroxyprogesterone cannot accurately predict nonclassical congenital adrenal hyperplasia in children and adolescents ... Hypertensive forms of adrenal hyperplasia (ie, 11-beta-hydroxylase deficiency and 17-alpha-hydroxylase deficiency) are ...
17a-Hydroxypregnenolone. Estrone. Phosphoadenosine. phosphosulfate. Estrone sulfate. Adenosine 3,5-diphosphate. 19-Oxoandrost ... alpha-steroid. 4-dehydrogenase. 1. UDP-. glucuronosyltransferase. 2B17. Steryl-. sulfatase. 17-Hydroxyprogesterone. ... 17-β-Estradiol-3-glucuronide. Uridine 5-diphosphate. Accumulation. Androstenedione. O. 2. H. 2. O. NAD. NADH. ... ene-3,17-dione. Dissipation. Estradiol. NADP. NADPH. 19-Oxotestosterone. 19-Hydroxyandrost-4-ene-. 3,17-dione. 19- ...
17a-Hydroxypregnenolone. Estrone. Phosphoadenosine. phosphosulfate. Estrone sulfate. Adenosine 3,5-diphosphate. 19-Oxoandrost ... alpha-steroid. 4-dehydrogenase. 1. UDP-. glucuronosyltransferase. 2B17. Steryl-. sulfatase. 17-Hydroxyprogesterone. ... 17-β-Estradiol-3-glucuronide. Uridine 5-diphosphate. Accumulation. Androstenedione. O. 2. H. 2. O. NAD. NADH. ... ene-3,17-dione. Dissipation. Estradiol. NADP. NADPH. 19-Oxotestosterone. 19-Hydroxyandrost-4-ene-. 3,17-dione. 19- ...
The syndrome of 17,20 lyase deficiency. J Clin Endocrinol Metab. 2012 Jan. 97(1):59-67. [QxMD MEDLINE Link]. [Full Text]. ... Females with 17-hydroxylase deficiency appear phenotypically female at birth but do not develop breasts or menstruate in ... CYP21A is the gene that codes for 21-hydroxylase, CYP11B1 codes for 11-beta-hydroxylase, and CYP17 codes for 17-alpha- ... Hypertensive forms of adrenal hyperplasia (ie, 11-beta-hydroxylase deficiency and 17-alpha-hydroxylase deficiency) are ...
Alpha-1 Antitrypsin Alpha-Fetoprotein (AFP) Amino Acids, Plasma Alanine b-Alanine ...
Alpha-Pregnanediol in mens urine is a significant metabolite of progesterone, and its levels can provide valuable insights ... Alpha-Pregnanediol and Beta-Pregnanediol are metabolites of progesterone, and they are used as surrogate markers because they ... It is metabolized via the 5-alpha metabolic pathway (= increased 5α-reductase activity). In contrast, the 5-beta metabolism ... Dehydroepiandrosterone is a 17-Ketosteroid produced primarily by the adrenal gland by side chain cleavage of 17-Hydroxy ...
11 Beta-Prostaglandin F2 Alpha, Urine, Random (MAYO via RPS) 84150, 82570 ... may have decreased concentrations of prostaglandin F2 alpha. If possible, discontinue for 2 weeks or 72 hours, respectively, ...
3-Keto-5-alpha-Steroid delta-4-Dehydrogenase use Testosterone 5-alpha-Reductase ... 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid ... 6-Oxo-PGF1 alpha use 6-Ketoprostaglandin F1 alpha 6-Oxoprostaglandin F1 alpha use 6-Ketoprostaglandin F1 alpha ...
... were considered as possessing greatest complexity Molecular and functional interactions between tumor necrosis factor-alpha ... 2005) undertook cytokine profiling pro prognosis of symptomatic RT-induced lung harm using a panel of 17 proinflammatory ... Ennobled 17-hydroxypregnenolone or pregnenolone concentrations perceive 3b-hydroxysteroid dehydrogenase deficiency from ... georgeslocksmiths.com/wp-content/interpretation/changes-17/brief-publication-2/]30 mg nimotop sale[/url]. He said it was ...

No FAQ available that match "17 alpha hydroxypregnenolone"

No images available that match "17 alpha hydroxypregnenolone"